ABSTRACT
BACKGROUND: Improved influenza vaccines are needed to control seasonal epidemics. This trial compared the protective efficacy in older adults of a quadrivalent, recombinant influenza vaccine (RIV4) with a standard-dose, egg-grown, quadrivalent, inactivated influenza vaccine (IIV4) during the A/H3N2-predominant 2014-2015 influenza season, when antigenic mismatch between circulating and vaccine influenza strains resulted in the reduced effectiveness of many licensed vaccines. METHODS: We conducted a randomized, double-blind, multicenter trial of RIV4 (45 µg of recombinant hemagglutinin [HA] per strain, 180 µg of protein per dose) versus standard-dose IIV4 (15 µg of HA per strain, 60 µg of protein per dose) to compare the relative vaccine efficacy against reverse-transcriptase polymerase-chain-reaction (RT-PCR)-confirmed, protocol-defined, influenza-like illness caused by any influenza strain starting 14 days or more after vaccination in adults who were 50 years of age or older. The diagnosis of influenza infection was confirmed by means of RT-PCR assay and culture of nasopharyngeal swabs obtained from participants with symptoms of an influenza-like illness. The primary end point was RT-PCR-confirmed, protocol defined, influenza-like illness between 14 days or more after vaccination and the end of the influenza season. RESULTS: A total of 9003 participants were enrolled and underwent randomization; 8855 (98.4%) received a trial vaccine and underwent an efficacy follow-up (the modified intention-to-treat population), and 8604 (95.6%) completed the per-protocol follow-up (the modified per-protocol population). Among RIV4 recipients, the RT-PCR-confirmed influenza attack rate was 2.2% (96 cases among 4303 participants) in the modified per-protocol population and 2.2% (96 cases among 4427 participants) in the modified intention-to-treat population. Among IIV4 recipients, the attack rate was 3.2% (138 cases among 4301 participants) in the modified per-protocol population and 3.1% (138 cases among 4428 participants) in the modified intention-to-treat population. A total of 181 cases of influenza A/H3N2, 47 cases of influenza B, and 6 cases of nonsubtypeable influenza A were detected. The probability of influenza-like illness was 30% lower with RIV4 than with IIV4 (95% confidence interval, 10 to 47; P=0.006) and satisfied prespecified criteria for the primary noninferiority analysis and an exploratory superiority analysis of RIV4 over IIV4. The safety profiles of the vaccines were similar. CONCLUSIONS: RIV4 provided better protection than standard-dose IIV4 against confirmed influenza-like illness among older adults. (Funded by Protein Sciences; ClinicalTrials.gov number, NCT02285998 .).
Subject(s)
Influenza Vaccines/immunology , Influenza, Human/prevention & control , Aged , Aged, 80 and over , Double-Blind Method , Female , Humans , Influenza A Virus, H3N2 Subtype/isolation & purification , Influenza A virus/isolation & purification , Influenza B virus/isolation & purification , Influenza Vaccines/adverse effects , Male , Middle Aged , Nasopharynx/virology , Proportional Hazards Models , Treatment Outcome , Vaccines, Inactivated/immunology , Vaccines, Synthetic/immunologyABSTRACT
To improve the clinical diagnosis of pneumococcal infection in bacteremic and nonbacteremic community-acquired pneumonia (CAP), a Luminex technology-based multiplex urinary antigen detection (UAD) diagnostic assay was developed and validated. The UAD assay can simultaneously detect 13 different serotypes of Streptococcus pneumoniae by capturing serotype-specific S. pneumoniae polysaccharides (PnPSs) secreted in human urine. Assay specificity is achieved by capturing the polysaccharides with serotype-specific monoclonal antibodies (MAbs) on spectrally unique microspheres. Positivity for each serotype was based on positivity cutoff values calculated from a standard curve run on each assay plate together with positive- and negative-control urine samples. The assay is highly specific, since significant signals are detected only when each PnPS was paired with its homologous MAb-coated microspheres. Validation experiments demonstrated excellent accuracy and precision. The UAD assay and corresponding positivity cutoff values were clinically validated by assessing 776 urine specimens obtained from patients with X-ray-confirmed CAP. The UAD assay demonstrated 97% sensitivity and 100% specificity using samples obtained from patients with bacteremic, blood culture-positive CAP. Importantly, the UAD assay identified Streptococcus pneumoniae (13 serotypes) in a proportion of individuals with nonbacteremic CAP, a patient population for which the pneumococcal etiology of CAP was previously difficult to assess. Therefore, the UAD assay provides a specific, noninvasive, sensitive, and reproducible tool to support vaccine efficacy as well as epidemiological evaluation of pneumococcal disease, including CAP, in adults.
Subject(s)
Antigens, Bacterial/analysis , Clinical Laboratory Techniques/methods , Pneumococcal Infections/diagnosis , Polysaccharides, Bacterial/isolation & purification , Streptococcus pneumoniae/chemistry , Urine/chemistry , Aged , Animals , Antibodies, Bacterial , Antibodies, Monoclonal , Female , Humans , Immunoassay/methods , Male , Mice , Mice, Inbred BALB C , Microspheres , Middle Aged , Sensitivity and SpecificityABSTRACT
BACKGROUND: The kidney is the only organ in which adenosine is a paracrine vasoconstrictor. This raises the possibility of using adenosine A1 receptor (AA1R) antagonists to selectively vasodilate the kidney in conditions, such as congestive heart failure, in which a selective decrease in renal vascular resistance would be salutary. The present study was undertaken to test the effectiveness of an AA1R antagonist as a renal vasodilator in patients with reduced kidney function superimposed on congestive heart failure. METHODS AND RESULTS: A randomized, double-blind, placebo-controlled, two-way crossover study was conducted in 32 outpatients with congestive heart failure and renal impairment (median glomerular filtration rate [GFR] 50 mL/min). Baseline GFR and renal plasma flow were assessed by iothalamate and para-amino-hippurate clearances, respectively, 3 hours before treatment. Subjects then received furosemide administered intravenously along with the AA1R antagonist, KW-3902 (rolofylline), or placebo. Clearance measurements were repeated, at intervals, throughout 8 hours beginning with the administration of the study drug. After a washout period of 3 to 8 days, subjects returned to undergo the crossover portion of the study. After the patients received KW-3902, GFR increased by 32% (P < .05 vs. placebo) and renal plasma flow increased by 48% (P < .005 vs. placebo) averaged over the ensuing 8 hours. Furthermore, those subjects who initially received KW-3902 returned for the crossover phase (median 6 days) with a persistent 10 mL/min increase in GFR more than their previous baseline (P < .05). CONCLUSIONS: AA1R activity contributes substantially to renal vascular tone in ambulatory patients with chronic congestive heart failure and impaired kidney function. Blockade of these receptors vasodilates the kidney and increases GFR. The increase in GFR seems to persist several days longer than predicted by pharmacokinetics, suggesting a resetting of one or more controllers among the complex network of physical and biological processes that interact to determine the kidney function. There may be short- or long-term benefits of using AA1R antagonists to improve kidney function in patients with congestive heart failure.
Subject(s)
Adenosine A1 Receptor Antagonists , Ambulatory Care/methods , Heart Failure/drug therapy , Kidney Diseases/drug therapy , Renal Plasma Flow/drug effects , Xanthines/therapeutic use , Adult , Aged , Aged, 80 and over , Cross-Over Studies , Double-Blind Method , Female , Heart Failure/physiopathology , Humans , Kidney/drug effects , Kidney/physiology , Kidney Diseases/physiopathology , Kidney Function Tests/methods , Male , Middle Aged , Receptor, Adenosine A1/physiology , Renal Plasma Flow/physiology , Xanthines/pharmacologyABSTRACT
We undertook a multicenter, randomized, controlled, phase 1/2 clinical study to investigate the safety and efficacy of a fibrin sealant containing 4 IU/ml thrombin (FS 4IU) for the attachment of autologous sheet grafts in patients with deep partial-thickness or full-thickness burn wounds. Fibrin sealant (FS 4IU) was compared with staples for adherence of sheet grafts in 40 patients. Patients had to have burn wounds measuring 40% TBSA or less with two comparable test sites measuring between 1% and 4% TBSA each. Wound beds were prepared before treatment assignment, which was randomized. Percent area of hematoma/seroma at Day 1 (P = .0138) and questionable viability at Day 5 (P = .0182) were significantly less for FS 4IU-treated sites. Median percent area of graft survival on Day 14 was 100% for both treatments (P = .3525). The percentage of completely closed sites generally was greater for FS 4IU-sites on Days 5 to 91; the maximum difference occurred at Day 28 (79.5% vs 59%; P = .0215). The safety profile of FS 4IU was excellent as indicated by the lack of any related serious adverse experiences. These findings indicate that FS 4IU is safe and effective for fixation of skin grafts, with outcomes similar to or better than staple fixation. The data suggest that FS 4IU is a promising candidate for further clinical studies focusing on skin graft adhesion and burn wound healing.
Subject(s)
Burns/surgery , Fibrin Tissue Adhesive/therapeutic use , Skin Transplantation/methods , Sutures , Thrombin/therapeutic use , Transplantation, Autologous , Treatment Outcome , Wound Healing , Adolescent , Adult , Aged , Child , Female , Fibrin Tissue Adhesive/adverse effects , Graft Survival , Humans , Male , Middle Aged , Thrombin/adverse effectsABSTRACT
OBJECTIVE: : To determine whether infrared tympanic thermometry (ITT) measurements more accurately reflect core body temperatures than axillary, forehead, or rectal measurements during fever cycles in children. DESIGN: : Prospective cohort study. SETTING: : Pediatric and cardiac intensive care units at a tertiary care children's hospital. PATIENTS: : Critically ill children <7 yrs of age with indwelling bladder catheters. INTERVENTIONS: : Simultaneous temperatures were recorded during both febrile and nonfebrile periods using ITT, indwelling bladder (core), axillary, forehead, and indwelling rectal measurements in 36 children. MEASUREMENTS AND MAIN RESULTS: : Overall ITT measurements were 0.03 +/- 1.43 degrees F less than core temperature measurements. In comparison, rectal, forehead, and axillary measurements averaged 0.62 +/- 1.44, 0.56 +/- 1.81, and 1.25 +/- 1.73 degrees F less than core temperature measurements. ITT measurements had better agreement with core measurements during increasing and decreasing temperature cycles. Receiver operating characteristic analysis performed on increasing and decreasing temperature cycle data revealed that ITT measurements performed well, with an area under the curve of 0.855 (95% confidence interval, 0.797-0.913) in comparison with rectal measurement area under the curve of 0.777 (95% confidence interval, 0.701-0.853), forehead measurement area under the curve of 0.710 (95% confidence interval, 0.715-0.888), and axillary measurement area under the curve of 0.664 (95% confidence interval, 0.579-0.750). CONCLUSIONS: : ITT measurements more accurately reflect core temperatures than any other measurement site during febrile and nonfebrile periods in children. ITT measurements are a reproducible and relatively noninvasive substitute for bladder or rectal measurements in febrile children.
Subject(s)
Body Temperature , Fever/diagnosis , Thermography/methods , Tympanic Membrane , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Predictive Value of Tests , Prospective Studies , Sensitivity and Specificity , ThermometersABSTRACT
In the course of preparing a revision to Chapter (111) of the U.S. Pharmacopeia, the revision committee came to a unanimous agreement that the method for assessing parallelism that is currently presented in (111) and in the European Pharmacopeia's Chapter 5.3 is flawed and should be replaced. The symptoms are that perfectly acceptable assay results may fail due to good precision and that obviously faulty assay results may pass due to poor precision. The flaw is that the wrong statistical technique has been used. We propose an alternative approach based on the equivalence testing paradigm that does not have these shortcomings. Equivalence testing requires the establishment of equivalence limits. Specific approaches for establishing equivalence limits are discussed.
Subject(s)
Data Interpretation, Statistical , Pharmacopoeias as Topic/standards , Pharmaceutical Preparations/metabolism , Reproducibility of Results , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/standards , Technology, Pharmaceutical/statistics & numerical data , Therapeutic EquivalencyABSTRACT
Pseudobulbar affect (PBA) or pathological laughing and crying (PLC) is a disorder of affect that occurs in about 10% of multiple sclerosis (MS) patients. The objective of this study was to validate the CNS Emotional Lability Scale (CNS-LS) in MS patients and to correlate the results with the frequency and intensity of episodes of PLC. Physicians at seven private practice referral centers in the United States made a diagnosis concerning PLC based on patient interviews. Clinical coordinators separately administered the CNS-LS, a self-report measure of PLC with seven questions, to MS patients, including patients known to exhibit PLC, patients thought to be free of PLC, and newly diagnosed patients where PLC status was unknown, and the physician was blinded as to the results. A receiver operating characteristic (ROC) curve analysis was performed to define a cut-off best correlating with the physician's diagnosis. Of 90 MS patients selected to complete the survey, 50 were physician diagnosed with PLC; 40 were without PLC, and 15 of these 90 patients were newly diagnosed with MS (<6 months). Scores of 17 or higher corresponded to a sensitivity of 0.94 and a specificity of 0.83 (LR+ = 5.5, LR- = 0.07); 89% of patients were correctly diagnosed. The area under the ROC curve was 0.95. Symptoms were greater in patients diagnosed as PLC than in non-PLC patients as evidenced by mean number of episodes/week, number of days/week with episodes, duration of an episode and total time in an episode. Similar results were observed if patients were classified as PLC or non-PLC according to CNS-LS score > or = 17, suggesting that the CNS-LS is a valid measure for the assessment of PLC in MS patients and could be a useful instrument for clinical and research purposes.
Subject(s)
Crying , Emotions , Laughter , Multiple Sclerosis/diagnosis , Multiple Sclerosis/psychology , Neuropsychological Tests/standards , Adult , Aged , Evaluation Studies as Topic , Female , Humans , Male , Middle Aged , Reproducibility of Results , Surveys and QuestionnairesABSTRACT
Echocardiographic assessment of cardiac function can be quite difficult in the intensive care unit and may require transesophageal echocardiography (TEE). We therefore compared harmonic imaging alone or in combination with contrast to TEE in 32 consecutive patients in the intensive care units who were considered technically very difficult (> or =50% of the 16 segments not visualized from any view). Excellent or adequate endocardial visualization was achieved in 13% of segments with fundamental imaging, 34% with harmonic imaging, and 87% with contrast (p < 0.0001); the latter success rate was similar to TEE (87% vs 90%; p = NS). When TEE was used as the standard, agreement in exact interpretation of wall motion increased from 48% for fundamental imaging to 58% with harmonic imaging, and reached 70% with contrast (p <0.0001). Contrast had the best sensitivity (89%) for detecting wall motion abnormalities. Estimation of ejection fraction was possible in 31% with fundamental imaging, 50% with harmonic imaging, and in 97% with contrast. Ejection fraction quantitated by contrast enhancement correlated best with TEE (r = 0.91). Cost-effectiveness analysis revealed that contrast echo was cost-effective compared with TEE in determining regional and global ventricular function, with a cost saving of 3% and 17%, respectively. Thus, contrast echocardiography provides an accurate, safe, and cost-effective alternative to TEE for evaluating ventricular function in technically very difficult studies.